Lenvima (lenvatinib) — United Healthcare

Initial criteria

• Diagnosis of thymic carcinoma
• One of the following:
• Used as a single agent for those who cannot tolerate first-line combination regimens
• Used as a second line therapy in unresectable locally advanced disease, solitary metastasis or ipsilateral pleural metastasis, or extrathoracic metastatic disease

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Lenvima therapy

Approval duration

12 months